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Chapter 1
Introduction
1.1 Overview of the endocannabinoid system
The endocannabinoid system (ECs) remained unknown till the ﬁrst part of 1990th, when the ﬁrst cannabi-
noid receptor, cannabinoid receptor 1 (CB1), was discovered in the brain [1]. The cannabinoid receptor
2 (CB2), instead, was found in immune cells in 1993 [2].The presence of these two type of G-protein
coupled receptors (GPCR) could be only explained with the presence of endogenous eCBs. In fact,
immediately after the discovery of the receptors, a series of endogenous ligands for the cannabinoid re-
ceptors have been identiﬁed and called endocannabinoids (eCBs). Among them, the two most present
in biological tissues and most studied, are N-arachidonoylethanolamine, also known as andandamide
(AEA) and 2-arachidonylglycerol (2-AG) [3]. ECBs are lipid mediators that mime the action of Δ9-
tetrahydrocannabinol (Δ9-THC), an exogenous psychoactive compound present in Cannabis plants (Fig-
ure 1.1).
Figure 1.1: Chemical structure of Δ9-THC
From that moment chemistry, metabolism, biochemistry and pharmacology of ECs have been strongly
6
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investigated (Figure 1.2). It is implicated in the regulation of several physiological processes like immune
functions, neuroprotection, pain regulation, cancer and cardiovascular diseases. It is clear that, a dysreg-
ulation of ECs could lead to pathological conditions so, the interest in trying to ﬁnd new pharmacological
strategies in order to reactivate the normal activity of this system, is still growing [4].
Figure 1.2: Components of the endocannabinoid system (Mark Rau)
1.2 Endocannabinoids
1.2.1 How they work
Endocannabinoids are synthetized on demand in a Ca2+-dependent manner in response to physiological
stimuli. This means that the biosynthesis is immediately followed by their release. Neuron depolarization
or activation of Gq-coupled receptors, lead to an increase of [Ca2+] which is the main cause of the release
of eCBs from phospholipidic precursors [5]. ECBs act as retrograde messengers [6], meaning that they
are released from the postsynaptic cell and activate receptors present on the presynaptic terminal. This
activation of presynaptic receptors can produce an alteration on the production of neurotransmitters, a
process known as transient and long lasting reduction [7]. The presynaptic eﬀects that eCBs have on the
release of neurotransmitters, are called in a diﬀerent way depending on the involvement of γ-Aminobutyric
Acid (GABA) or Glutamate transmissions. The depolarization-induced suppression of inhibition (DSI)
is activated from a voltage dependent inﬂux of Ca2+ on the postsynaptic terminal. The eﬀect on the
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presynaptic terminal is the inhibition of GABA release, meaning a reduction of the inhibitory signal.
The depolarization-induced suppression of excitation (DSE), acts with the same mechanism of DSI, but
opposite in sign because of the glutamatergic target, and the ﬁnal eﬀect is a reduction of excitatory signal
[8]. The retrograde mechanism of eCBs is also important for the long-term synaptic plasticity, divided in
long-term depression (LTD) and long-term potentation (LTP). ECBs induce LTD in the striatum and in
the nucleus, whereas they prevent LTP in the hippocampus [7].
1.2.2 AEA and 2AG
The two most abundant eCBs in tissues are AEA and 2AG. AEA has been discovered and then isolated
in 1992 [9]. Chemically, it is the ethanolamide of arachidonic acid (AA) (Figure 1.3), it belongs to
N-acetylethanolamines (NAEs) family and it acts as a partial agonist on both CB1 and CB2 [10].
Figure 1.3: Chemical structure of AEA
AEA is biosynthetized following diﬀerent pathways from phospholipidic precursors. The main one
starts with an acyl chain transfer, catalyzed by a Ca2+-dependent N-acyltransferase (NAT), from the sn-1
position of a glycerophospholipid to the amino group of the hydroxyethyl moiety of phophatidylethanolamine
(PE), to form N-acylphophatidylethanolamine (NAPE). Then, the phospholipase D (NAPE-PLD) cat-
alyzes the hydrolysis of NAPE to form AEA and phosphatidic acid. In the second one, AEA formation is
due to the deacylation of NAPE made by α/β-hydrolase 4 (ABHD4) to form glyceropohpho-anandamide
and the following hydrolysis made by the phosphodiesterase glicerophophodiester-phosphodiesterase-1
(GDE1). Lastly, AEA can be synthetized from the hydrolysis of NAPE catalyzed by phospholipase C
to form phosphoanandamide. The ﬁnal step is a phosphate group removing made by the phosphatase
PTPN22 [11]. 2AG has been identiﬁed and isolated from the canine gut in 1995 [12]. It is the glycerol
ester of AA (Figure 1.4) and acts as a full agonist on both cannabinoid receptors CB1 and CB2 [13].
Figure 1.4: Chemical structure of 2AG
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The main biosynthetic pathway starts with the hydrolysis of membrane phospholipids catalyzed by
Phospholipase C (PLC), to form 1,2-diacylglycerol (DAG). DAG is then converted to 2AG by diacylglyc-
erol lipase (DAGL) [14]. Once the eCBs are released in the extracellular part, they activate the receptors
and then, are removed by intracellular uptake and degraded [15]. Considering the lipophilic structure of
most of the endocannabinoid molecules, it could be concluded that they easily pass through the cell mem-
brane. Despite their structures, the traﬃcking of eCBs through the membrane is regulated by a putative
endocannabinoid membrane transporter (EMT). EMT is responsible for the bidirectional movement of
both 2AG and AEA, even if AEA showed higher selectivity towards the transporter. The interest in EMT
activity on 2AG and AEA is still growing and several inhibitors of this transporter have been synthetized.
These inhibitors could have a potential role and represent good alternatives in regulating eCBs levels
[16]. Two hydrolases are implicated in the main inactivation pathway, both for AEA and 2AG. Regarding
AEA, the main hydrolytic enzyme is the fatty acid amide hydrolase (FAAH). This is an integral membrane
serine hydrolase protein, characterized by a Ser-Ser-Lys catalytic triade, which has the highest density in
the brain and in the liver. It hydrolyzes the amidic bond to form AA and ethanolamide. AEA is the main
target of FAAH respect to the other NAEs. The other enzyme responsible of the inactivation of AEA is
N-acylethanolamine-hydrolyzing acid amidase (NAAA) which is mainly present in the immune cells [17].
The monoacyl-glycerol lipase (MAGL) is the main degrading enzyme for 2AG in the brain, responsible of
85% of total brain membrane 2AG hydrolase activity. Results of its hydrolytic action on the esteric bond
are AA and glycerol. Other two minor enzymes present in the brain, responsible of the metabolism of
2AG, are α/β-Hydrolase-6 (ABHD-6) and α/β-Hydrolase-12 (ABHD-12). The results of their hydrolysis
are the same as the ones of MAGL activity, AA and glycerol (Figure 1.5) [18].
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Figure 1.5: Biosynthetic and metabolic pathways of AEA and 2AG
[17]
The inhibition of FAAH and MAGL attracted recent studies as a possible mechanism to regulate and
modulate eCBs levels. Several inhibitors have been synthetized and the scaﬀold used as template for
successive modiﬁcation and improvement. The inhibition of FAAH activity lead to an increase of AEA
levels. URB-597 (Figure 1.6) is a selective carbamate-based inhibitor of FAAH, without activity on other
cannabinoid targets. Its activity is not accompanied by CB1-like behavioral side eﬀects, known as tetrad:
analgesia, hypomotility, hypothermia and catalepsy [19]. JZL-184 (Figure 1.6) have been described as
highly eﬃcacious and selective inhibitor of MAGL activity on 2AG. JZL-184 did not aﬀect the levels
of AEA, other NAEs or monoacylglycerols. Inhibitory activity of MAGL led to an increase of 2AG
concentration in the brain but a series of cannabimimetic side eﬀects have been shown [20].
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(a) URB-597 (b) JZL-184
Figure 1.6: Structure of a FAAH inhibitor (URB-597) and a MAGL inhibitor (JZL-184)
1.2.3 Other endocannabinoids and endocannabinoid-like compounds
Except the well-known AEA and 2AG, the panorama of endocannabinoids includes other compounds.
Virodhamine is the ethanolamine ester of AA (Figure 1.7), it acts as a full agonist on CB2 and as a
partial agonist or antagonist on CB1 receptors [21]. Despite some current debates, the 2-arachidonyl-
glyceryl ether (2AGE), also known as noladin-ether (NE) (Figure 1.7), is another compound classiﬁed
as endocannabinoid and it binds to CB1 and weakly to CB2 receptors [22]. N-arachidonoyl-dopamine
(NADA) (Figure 1.8) was discovered in the brain in 2002 and acts as an agonist on CB1 receptor and
on the vanilloid receptor TRPV1 [23]. There are other compounds called endocannabinoid-like which
exert cannabimetic eﬀects without activating cannabinoid receptors and are able to prevent the enzy-
matic metabolism of endocannabinoids [24]. Among these compounds, palmitoylethanolamide (PEA),
oleoylethanolamide (OEA) and linoleoylethanolamide (LEA), which belong to the NAEs family, are the
most studied. (Figure 1.9). PEA has an activity on both TRPV1 and PPARγ receptors that mediate its
anti-inﬂammatory and analgesic eﬀects [25]. Both PEA and OEA activate GPR55 receptors [26]. OEA
and LEA are known for their eﬀects on appetite [27] [28].
(a) Virodhamine (b) NE
Figure 1.7: Chemical structures of Virodhamine and NE
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Figure 1.8: Chemical structure of NADA
(a) PEA (b) OEA (c) LEA
Figure 1.9: Chemical structures of endocannabinoid-like compounds
1.2.4 Receptors and ligands
1.2.4.1 CB1 and CB2
CB1 and CB2 receptors are part of the GPCR superfamily, mainly coupled with Gi/o proteins. Once
activated by a ligand, they both inhibit adenylyl cyclase (AC) and activate mitogen-activated protein
kinase (MAPK). CB1 receptor is also coupled with Gs protein (Figure 1.10) [10].
Figure 1.10: Pathways associated with CB receptors activation
[29]
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There are homologies between CB1 and CB2 receptors: 44% for the total structure and 68% regarding
the transmembrane domain (Figure 1.11) [2]. Since they are GPCR they show the typical structure of
seven transmembrane domains.
Figure 1.11: CB1 and CB2 structures
CB1 receptors are most abundant in the Central Nervous System (CNS) and in the brain, especially
in hippocampus, cerebellum and striatum [30]. The activation of CB1 has eﬀects on cognition, memory,
control of motor functions and analgesia [10]. CB1 receptors are more abundant in GABAergic interneu-
rons than in glutamatergic principal neurons [31]. There are evidence of the presence of CB1 also in some
peripheral tissues like gastrointestinal tract, liver, kidney, lungs [32]. CB2 receptors are mainly present in
cells and organs of the immune system, such as tonsils, B and T cells, monocytes, macrophages and they
are highly expressed in spleen tissue [33]. CB2 are also found in the brain and when activated, they are
able to modulate the migration of immune cells and the release of cytokines in and outside the brain [32].
Since their discovery, the activity of agonist, antagonist and inverse agonist for these two type of recep-
tors have been investigated. Most of the pharmacological eﬀects are due to the activity on CB1 receptors
which are mainly present in the CNS. Ligands for this type of receptor have been studied because of their
potential role to treat pain, cardiovascular and gastrointestinal diseases, obesity. Unfortunately, these
pharmacological beneﬁts are combined with undesirable psychotropic eﬀects that limit the progression of
CB1 ligands. Anyway, they now have an important role for in vitro and in vivo studies as comparison.
Nowadays, the studies are focused on selective CB2 receptor ligands, especially for pain treatment and
neurological diseases. The activation of CB2 receptors avoid the central side eﬀects observed for CB1 [34].
CP-55,940 and WIN-55,512-2 are the two major non-selective endocannabinoid receptor agonists which
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are used as control in laboratory experiments (Figure 1.12).
(a) CP-55,940 (b) WIN-55,212-2
Figure 1.12: Chemical structures of CP-55,940 and WIN-55,212-2
1.2.4.2 Other receptors
The presence of the G-protein coupled receptor GPR55 in brain, vascular endothelium and immune system
has been showed and its activity is regulated by both natural and synthetic cannabinoid compounds.
Virodhamine activates GPR55, CB1 and CB2 receptors with a higher selectivity compared with AEA.
This activation is important for a cannabinoid vascular-tone controlling. Eﬀects of PEA on immune
system are mainly due to modulation of CB2 receptors but, it acts also as a potent agonist on GPR55 and
this could have a role in immune cell migration and activation. It has been showed that AEA activated
GPR55 with the same potency than CB1 and CB2. 2AG, PEA and Virodhamine, instead, are more potent
at activating GPR55 than CB1 and CB2 [26]. Transient receptor potential vanilloid-type-1 (TRPV1) is
a non-selective cation channel implicated in pain transmission, which can be found in both peripheral
and central terminals of sensory neurons. This receptor can easily be activated during inﬂammation and
the expression of TRPV1 is increased during neuropathic pain. The main exogenous ligand of TRPV1 is
the capsaicin, present in chili peppers, which has an analgesic activity. Among the eCBs, AEA acts as
a partial agonist on TRPV1 and together with CB1 activation, it decreases the neuropathic pain. Also
NADA, 2AG and PEA are ligands that can activate these type of receptors [35].
1.3 Cyclooxygenase-2 (COX-2)
Cyclooxygenase (COX) is the enzyme responsible for the ﬁrst step in the metabolism of AA to gener-
ate prostaglandins (PGs). PGH2s which are formed from COX-2 activity on AA, are metabolized by
downstream synthases to form prostaglandin-E2 (PGE2), prostaglandin-D2 (PGD2), prostaglandin-F2α,
prostacyclin (PGI2) and thromboxane-A2 (TxA2) (Figure 1.13). PGs are local mediators of inﬂammation
and modulators of physiological functions, like maintenance of gastric mucosal integrity, modulation of
CHAPTER 1. INTRODUCTION 15
renal vascularization and renine release. The inhibition of this pathway, is the main contributor of the
pharmacological eﬀects of non-steroidal anti-inﬂammatory drugs. The most common side eﬀects of this
type of drugs are gastrointestinal damages and ulcer, caused by the inhibition of the formation of PGs in
intestine and stomach. [36]
Figure 1.13: Prostaglandins cascade
[37]
Two isoforms of COX exist and they are called COX-1 and COX-2. COX-1 was ﬁrst puriﬁed from ram
seminal vesicles and was cloned in 1988 [38]. Subsequently, a second inﬂammatory-mediated COX isoform
was identiﬁed and called COX-2 [39] [40]. COX-2 is a homodimer composed by two diﬀerent monomers,
but it behaves as functional heterodimer with an allosteric site and a catalytic site. The active site of
COX-2 is located inside the catalytic domain, but recent studies discovered that the two monomers of this
enzyme are functionally interdependent. COX-2 is also responsable for the metabolism of the two major
eCBs, 2AG and AEA. It oxygenates and inactivates 2AG to form prostaglandin-glycerol esters (PG-GEs)
and AEA to produce prostaglandin-ethanolamides (PG-EAs or prostamides) [41]. (Figure 1.14)
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Figure 1.14: COX-2 activity on AEA and 2AG
[42]
PG-GEs and prostamides act on diﬀerent receptors as compared to classic prostaglandin, which have
not been identiﬁed, yet [43]. They could have an action as precursor of common PGs or act as signal
mediators [44]. These compounds are known to induce pro-inﬂammatory and hyperalgesic eﬀects and
to induce excitoxic damages, eﬀects that could lead to an imbalance between neuroprotective eﬀects of
2-AG and potential neurotoxic eﬀects of its COX-2 metabolites [45]. Recent studies showed that the two
monomers of COX-2 are functionally connected and the binding of a substrate or inhibitor at one of the
two active sites, modiﬁes the properties of the other one. Lower concentrations of inhibitors are required
to inhibit the allosteric site (responsible of the eCBs oxygenation) than the ones required for the catalytic
site (responsible of the AA oxygenation). Inhibitor binds to the ﬁrst subunit of the homodimer and
induces a conformational change in the second subunit, responsible of the eCBs oxygenation. The result
of this process is the inhibition of the eCBs oxygenation. In order to inhibit also the AA oxygenation,
another molecule of inhibitor has to bind on the other subunit (Figure 1.15). These interesting ﬁndings
pushed studies to focus on the selective inhibition of COX-2, trying to inhibit eCBs oxygenation without
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aﬀecting AA and PGs. A compound with this type of action is called Substrate Speciﬁc Inhibitor (SSI)
of COX-2-mediated endocannabinoid oxygenation. It has been shown that (R)-Profens like Flurbiprofen,
Naproxen and Ibuprofen act this type of COX-2 inhibition [46].
Figure 1.15: Mechanism of a COX-2 SSI
[46]
1.4 4'-O-Methylhonokiol
4-O'-Methylhonokiol (MH), a biphenyl compound, (structure Figure 1.16) is the main component of the
Magnolia grandiﬂora oil seeds (Figure 1.17) The seeds of this plant, have been known in the Mexican
medicine for their antispasmolyitc and anti-inﬂammatory eﬀects [47]. Magnolol and Honokiol (structure
Figure 1.16) , known for their anti-inﬂammatory, anti-allergic and anti-bacteria activities, are secondary
components of this oil. These bioactive compounds are mainly present in a diﬀerent species of this plant,
the Magnolia oﬃcinalis [48].
Figure 1.16: Chemical structures of Magnolol, Honokiol and MH
[47]
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(a) Tree (b) Seeds
Figure 1.17: Magnolia grandiﬂora
MH is a selective ligand for CB2 receptor. It acts as a partial agonist (they can behave as agonists
or antagonists depending on the conditions) in the GTPγS binding assay compared to the full agonist
2AG, which induces the maximal response. The GTPγS binding assay measures the level of G protein
activation following agonist occupation of GPCR. MH is also known to act as full agonist in the CB2
receptor-mediated inhibition of forskolin-induced cAMP production. In this assay it reproduces the same
eﬀects of the full agonist 2AG in the cAMP pathways [49]. Finally, MH acts as a full agonist at the
level of [Ca2+] intracellular. Diﬀerent derivatives of MH have been tested to explore which parts of the
scaﬀold were important for the CB2 binding. In this study, MH appeared to have the most active scaﬀold
compare to the others derivatives. Hydrogenation, epoxidation or hydroxylation of the side chains of
MH did not change the binding aﬃnity and, in some cases, it was abolished. Modiﬁcation on the -OH
and -OCH3, such as hydrophobic or bulky groups, led to a decrease in the binding activity [47]. A
similar study has been done studying the activity of diﬀerent derivatives on COX-1 and COX-2. Also
in this case MH showed the best proﬁle, with a small selectivity towards COX-2. [50]. MH is studied
for its anti-inﬂammatory and neuroprotective eﬀects in Alzheimer Disease (AD) murine models. AD is
the most common neurodegenerative disease which is characterized by cerebral deposition of the amyloid
β peptide. This peptide is a critical factor in AD and leads to a series of neuronal damages due to the
increase of cellular death. Anti-oxidative and anti-amyloidogenesis eﬀects of MH ameliorates LPS-induced
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memory impairment and inhibits neuroinﬂammation [51]. MH also suppresses the oxidative damages of
β-amyloid induced memory impairment murine models [52]. It also shows anti-osteoclasteogenic eﬀects
[47]and induces anxiolytic eﬀects through the activation of GABAergic transmission. GABA is the main
inhibitory neurotransmitter and its system is the most common target of the anxiolytic drugs. MH has an
agonistic eﬀect on GABAA receptors which are heteromeric Cl− channels. Activation of these channels
leads to an inﬂux of Cl− into the cell that causes hyperpolarization and ﬁnally inhibition of cellular
activity [53]. In rat MH showed high systemic clearance and an extensive cytochrome P450 (CYP450)
hepatic metabolism, where it is transformed in Honokiol. MH has a low oral bioavailability and this could
be due to its extensive ﬁrst-pass hepatic metabolism. Importantly for its therapeutic application, is the
ability to pass the Blood-Brain-Barrier (BBB) [54].
Chapter 2
Aim of the thesis
The selective inhibition of COX-2-mediated 2AG and AEA oxygenation without aﬀecting AA and PGs
levels could be an interesting alternative therapeutic opportunity to treat inﬂammatory processes. Com-
pounds that acts in this manner are called substrate speciﬁc inhibitors (SSIs) of COX-2-mediated en-
docannabinoid oxygenation. In this way, the oxygenation of 2AG and AEA is inhibited as well as the
formation of PG-GEs and prostamides, while of AA and PG levels should not be aﬀected [46]. 4'-
O-Methylhonokiol (MH) is a biphenyl compound extracted from oil seeds of Magnolia grandiﬂora. It
is known for its several properties, such as anti-inﬂammatory, anxiolytic, anti-osteoclasteogenic, anti-
oxidative and neuroprotective [47] [51] [52] [53]. MH acts as a CB2 receptor agonist and showed to be a
substrate speciﬁc inhibitor of COX-2-mediated endocannabinoid oxygenation [49]. There is evidence that
COX-2 is expressed in critical location of mammalian kidney [55]. The SSI activity of MH on COX-2 in
the kidney could play an important therapeutic role, since PGs have a key physiological role in this organ
in terms of vascularization and protection.
The aim of my thesis was to quantify endocannabinoids and prostaglandins in mice that were injected
with MH. In order to study the eﬀects of this molecule in vivo, Swiss CD1 mice were treated with three
diﬀerent doses of MH or control, injected intraperitoneally (i.p.). After 2 hours the animals were sacriﬁced
and organs collected. The quantiﬁcation of endocannabinoids and prostaglandins in kidney, brain, liver,
lung and spleen was done using a LC-MS/MS method currently used in the laboratory of Prof. Gertsch.
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Chapter 3
Materials and Methods
3.1 Animals treatment
24 females, 8 weeks old SWISS CD1 mice (Figure 3.1) were used for this experiment. All animals were
kept in a temperature-controlled environment with a 12 h light-dark cycle and were allowed free access
to food and water at all times and were cared for in accordance with National Institute of Health (NIH)
guidelines. Animals were injected intraperitoneally (i.p.) with dimethyl sulfoxide (DMSO) as vehicle and
with 3mg/kg, 10mg/kg and 20mg/kg of MH. They were divided in four diﬀerent groups, each one with a
diﬀerent treatment. After 2 hour mice were anesthetized and sacriﬁced. Brain, spleen, liver, kidneys and
lungs were collected and stored at -80°C until use.
Figure 3.1: SWISS CD1 mouse
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3.2 LC-MS/MS
3.2.1 Chemicals and reagents
All chemicals and reagents used for LC-MS/MS were of the purest analytical grade. AEA, AEA-d4,
2-AG, 2-AG-d5, PEA, PEA-d5, OEA, OEA-d4, LEA, LEA-d4, arachidonic acid (AA), AA-d8, PGD2,
PGE2, Corticosterone and Progesterone were purchased from Cayman Chemical Europe, Tallinn, Estonia.
MH was kindly provided by Prof. Schühly, University of Gratz ([47]). HPLC-grade methanol (CH3OH),
HPLC-grade acetonitrile, ammonium acetate and formic acid were obtained from Sigma-Aldrich, Stein-
heim, Germany. HPLC-grade ethyl acetate and hexane were obtained from Acros Organics, New Jersey,
USA. Deionized water (18.2 MΩ Ö cm) was obtained from an ELGA Purelab Ultra Genetic system (VWS
UK Ltd, ELGA LabWater, UK).
3.2.2 Samples extraction
For the extraction, tissues (brain, spleen, liver, kidneys and lungs) were weighted (~40mg) when still frozen
and transferred to 2 mL Microcentrifuge vials (XXTuﬀ Microvials, BioSpec, Oklahoma, USA) containing
3 Chrome-Steel Beats (2.3 mm dia, BioSpec, Oklahoma, USA) and 0.1 M Formic Acid. Samples were
homogenized using a 24 positions Mini bead beater (BioSpec Products, Inc, Bartlesville, OK, USA), then
rapidly transferred to glass tubes containing 1.5 mL of ethyl acetate/hexane (9:1) 0.1% formic acid and
5µL of the Internal Standard mixture (IS), strongly vortexed for 30 seconds and sonicated (Sonicator
Merck-Gruppe) in cold bath for 5 mins. Samples were centrifuged at 3000 rpm for 10 min at 4°C and
kept for 1h at -20°C to freeze the aqueous phase. The upper organic phase was recovered in plastic tubes
and, dried in a speed vacuum. The extracts were reconstituted in 50 µL of ACN:EtOH 8:2 and 10 µL
were injected in the LC-MS/MS system.
3.2.3 LC-MS/MS conditions
A hybrid triple quadrupole 4000 QTRAP mass spectrometer (AB Sciex Concord, Ontario, Canada) was
used with a Shimadzu UFLC (Shimadzu Corporation, Kyoto, Japan) with cooled auto-sampler. Sam-
ple temperature was maintained at 4°C in the auto-sampler prior to analysis. The LC columns were
Reprosil-PUR C18 column (3 μm particle size; 2 Ö 50 mm, Dr. A. Maisch, High Performance LC-GMBH,
Ammerbuch, Germany) maintained at 40° C. The system was operated in positive and negative mode
with 2 diﬀerent elution mobile phases and gradient method. In positive mode the elution mobile phases
were: water, 2 mM ammonium acetate, 0.1% formic acid (solvent A) and methanol, 2 mM ammonium
CHAPTER 3. MATERIALS AND METHODS 23
acetate (solvent B). The gradient started at 15% B, increasing linearly to 70% at 3.5 min, then to 99%
at 8 min, maintained until 12 min, with subsequent re-equilibration at 15% for further 2.5 min. The ﬂow
rate was 0.35mL/min. (Fig 3.2). In negative mode the gradient started at 5% B, increasing linearly to
40% at 3 min, then to 65% at 9 min and linearly again to 95% at 10min; this was maintained until 14
min, with subsequent re-equilibration at 5% for further 3 min. The ﬂow rate was 0.3mL/min (Fig 3.3).
In this mode the organic mobile phase (B) was substituted with acetonitrile 0.1% formic acid to minimize
crosstalk between analytes with the same mass ([M-H]-, m/z 351 PGE2-D2) (Fig 3.4).
Figure 3.2: Gradient curve of the positive mode.
Figure 3.3: Gradient curve of the negative mode.
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Figure 3.4: Mass spectrum of PGE2 upon negative ionization.
The dominant peak is m/z 351.2 which corresponds to the [PGE2-H]- ion. The spectrum shows the
fragmentation pattern of m/z 351.2. The loss of H2O lead to two of the fragments observed: m/z 333.1
(-H2O) and 315 (-2H2O). PGD2, being isomer of PGE2, exhibits identical fragmentation patterns (iden-
tical precursor and product ions) and requires the development of high resolution liquid chromatography
method for their separation
Peaks were integrated, and the Analyst software version 1.5 (AB Sciex Concord, Ontario, Canada) was
used for quantiﬁcation. Identiﬁcation of compounds in samples was conﬁrmed by comparison of precursor
and product ion m/z values and LC retention times with standards. The following Multiple Reaction
Monitoring (MRM) transitions were monitored for quantiﬁcation of the analytes: Positive mode: 2AG
m/z 379287, 379203 (IS: 2-AG-d5 384287); AEA m/z 348133, 34862 (IS: AEA-d4 35266);
MH m/z 281298, 281240, 281225 (IS: MH-d6 287246); Corticosterone m/z 347135, 347121,
34797 (IS: Corticosterone-d4 367121); LEA m/z 324109, 32462 (IS: LEA-d4 32866); OEA
m/z 326309, 32662 (IS: OEA-d4 33066), PEA m/z 300283, 30062 (IS: PEA-d5 30562),
Progesterone m/z 315109, 31597 (IS: PROG-d9 324100); NE m/z 365133, 365121 (IS: 2-AG-
d5 384287). Negative mode: AA m/z 303259, 30359 (IS: AA-d8 31159), PGE2 m/z 351271,
351315 (IS: PGE2-d4 355319); PGD2 m/z 351189.1 (IS: PGE2-d4 355319). Typical extracted
ion cromatograms are showed in the following ﬁgures.
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Positive mode:
(a) 2AG (b) 2AG-d5
Figure 3.5: 2AG and 2AG-d5
2AG is known to isomerize into 1AG. The method was developed to minimize isomerization but if present
the sum of the response of the two isomers was applied as suggested in several papers [56].
(a) AEA (b) AEA-d4
Figure 3.6: AEA and AEA-d4
(a) MH (b) MH-d6
Figure 3.7: MH and MH-d6
(a) Corticosterone (b) Corticosterone-d4
Figure 3.8: Corticosterone and Corticosterone-d4
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(a) LEA (b) LEA-d4
Figure 3.9: LEA and LEA-d4
(a) OEA (b) OEA-d4
Figure 3.10: OEA and OEA-d4
(a) PEA (b) PEA-d5
Figure 3.11: PEA and PEA-d5
(a) Progesterone (b) Progesterone-d9
Figure 3.12: Progesterone and Progesterone-d9
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(a) NE (b) 2AG-d5
Figure 3.13: 2AGE and 2AG-d5
Negative mode:
(a) AA (b) AA-d8
Figure 3.14: AA and AA-d8
(a) PGE2 (b) PGE2-d4
Figure 3.15: PGE2 and PGE2-d4
(a) PGD2 (b) PGE2-d4
Figure 3.16: PGD2 and PGE2-d4
PGE2-D2 are isomers and this is the best separation we could obtain using a C-18 reverse phase column.
PGE2-d4 was used also as internal standard for PGD2.
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Triplicate 11 calibration points were prepared in 0.1 % formic acid plus 1% bovine serum albumine
(BSA), and the appropriate matrix. The concentration of calibrators moved from 20 ng/mL to 50000
ng/mL for AA, 0.2 ng/mL to 500 ng/mL for LEA, PEA, OEA, PGD2, PGE2, Corticosterone, from 0.08
ng/mL to 200 ng/mL for AEA and Progesterone, 2 ng/mL to 5000 ng/mL for 2-AG and 8 ng/mL to
20000 ng/mL for MH. The calibrators and the amount of ISs were speciﬁcally design to measure the
amount of the analytes in the biological matrix to be studied. To ensure that were constant background
concentration of all endogenous analytes, bulk tissues were homogenized in 0.1% formic acid and used
for validation and calibration data set (the background was subtracted to spiked concentration levels).
The ratio (peak area of each analyte/peak area of internal standard), was calculated and used to ensure
linearity of the method. The slope, intercept, and regression coeﬃcient of those calibration lines were
determined. Analytes amount were normalized to the tissue weight and plotted in GraphPad Prism 5
r. The statistical signiﬁcance among groups was determined using a one-way ANOVA test followed by
Tukey's test. Statistical diﬀerences between control and treated groups were considered as signiﬁcant if
*P≤0.05 (**P≤0.01 and ***P≤0.001).
3.2.4 LC-MS/MS validation
In order to determine intraday (n=6) and interday (n=6 over a period of 8 separated days) precision
and accuracy, analytes were spiked into liver tissue at 3 concentrations representing the entire range of
concentration (LQC, low quality control, MQC medium quality control, HQC high quality control) and
homogenized with extraction solvent. Precision was calculated from the relative standard deviation of the
replicates (RSD), also known as coeﬃcient of variation (CV), and accuracy was calculated by comparison
of measured levels of spiked analytes with expected concentrations. A CV values of 20% was considered
to be acceptable for accuracy and precision at the lower quality control. Recovery for the only non-
endogenous analyte (MH) was calculated by comparison of the integrated area under the curve of the
analyte at low, medium, and high concentration with 100% standards (neat solution). For all the other
analytes, due to the endogenous nature of the eCBs, recovery was calculated by comparison of deuterated
analogue (IS). Evaluation of ion suppression eﬀects (matrix factor) was determined for non-endogenous
analytes (MH) as the ratio between the peak area of analyte spike into matrix after extraction and the peak
area of the analyte in neat solution. Values of 0.96 for LQC, 0.82 for MQC, 0.82 for HQC were obtained.
For the analytes already present in blank matrix itself, evaluation was performed with the deuterated
analogue. Matrix factor values were all closed to 1 (no matrix eﬀects) except for LEA, PEA, OEA which
values varied between 0.6-0.7 (ion suppression) indicating a signiﬁcant matrix ionization eﬀects in positive
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mode eﬀecting the ethanolamides. For the purpose of the study ethanolamides are minor analytes and
the overall quality of the method, especially for endocannabinoids, resulted to be sensitive, precise and
accurate. Examples of a set of validation data for an endogenous and non-endogenous analytes are showed
in the next tables (Table 3.1 and Table 3.2 ).
INTERDAY INTRADAY
LQC MQC HQC LQC MQC HQC
Nominal concentration (ng/mL) 32 256 3200 32 256 3200
30.93 229.75 3176.28 34.83 239.98 2497.47
25.43 246.80 2768.59 34.50 253.16 3470.31
34.83 273.19 3382.83 30.95 257.13 2797.51
34.50 277.98 3207.69 34.29 228.42 2722.79
32.98 254.51 2993.86 35.78 227.75 2423.54
33.31 294.54 3292.70 31.97 234.82 2469.82
Mean 32.00 262.79 3136.99 33.72 240.21 2730.24
RSD (+/-) 3.50 23.51 222.46 1.85 12.47 392.01
C.V. (%) (Precision) 10.94 8.94 7.09 5.49 5.19 14.36
% Nominal conc. (Accuracy) 99.99 102.65 98.03 105.37 93.83 85.32
Matrix factor 96.20 81.71 81.20
Recovery 101.79 93.23 107.46
Table 3.1: Quality control data for 2AG
INTERDAY INTRADAY
Nominal concentration (ng/mL) LQC MQC HQC LQC MQC HQC
32 256 3200 32 256 3200
9.10 59.44 828.23 10.53 57.30 739.50
8.23 65.45 739.87 8.78 69.72 764.86
8.64 70.16 886.43 6.71 73.12 811.64
8.02 66.75 827.75 10.98 65.27 894.20
9.87 60.23 835.22 12.17 54.18 750.38
7.73 64.45 835.22 10.25 64.13 766.11
Mean 8.60 64.41 825.45 9.90 63.95 787.78
RSD (+/-) 0.79 4.05 47.43 1.91 7.20 57.65
C.V. (%) (Precision) 9.19 6.28 5.75 19.29 11.25 7.32
% Nominal conc. (Accuracy) 107.45 100.65 103.18 123.80 99.93 98.47
Matrix factor 89.98 88.34 77.64
Recovery 101.09 94.33 92.28
Table 3.2: Quality control data for MH
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3.3 CB2 receptor binding assay
For the CB2 binding experiment, 20 µg of Chinese Hamster Ovary (CHO) membranes overexpressing CB2
receptors were used. CHO-cell stably transfected with the hCB2 receptor are routinely cultured in the
Gertsch's lab with the standard cell culture procedure (RPMI 1640 medium Sigma-Aldrich, Steinheim,
Germany) supplemented with 10% fetal bovine serum (Invitrogen), 400μg/ml Geneticin (G418) (Invivo-
gen), 1% penicillin-streptomycin (Sigma-Aldrich, Steinheim, Germany) at 37°C and 5% CO2. Membrane
preparation is also a common procedure used in various assays in the lab [Chicca et al. 2016 in press]. The
assay buﬀer was made by 50mM Tris-HCl, 2.5mM ethylenediaminetetraacetic acid (EDTA), 5mM MgCl2
and 0.5 % BSA and was prepared at pH 7,5. Membranes were diluted in the assay buﬀer and incubated
for 1.5 hours at room temperature with 0.5 nM [3H ]-CP55,940 (PerkinElmer Life Sciences, Waltham,
MA, USA) in the presence or absence of diﬀerent concentration of MH using DMSO as control and (R)-
WIN55,212-2 (Cayman Chemicals, Ann Arboe, MI, USA), to determine non-speciﬁc binding. After the
incubation time, membranes were ﬁltered through a GF/B ﬁlter which was previously presoaked for 1.5
hours at room temperature with 0.1% of polyethyleneimine (PEI). Then the GF/B ﬁlter was washed twelve
times with 150µL of the assay buﬀer and dried. Finally, the ﬁlter was incubated for 20 minutes at room
temperature with 45µL of the scintillation liquid MicroScint 20 (PerkinElmer Life Sciences, Waltaham,
MA, USA) and radioactive signal (cpm) was read using a Top-counter Tri-carb 2100 TR (PerkinElmer
Life Sciences, Waltaham, MA, USA).The concentration-dependent binding curve was measured for MH
and also for WIN55,212-2 as a control. Results were analyzed using GraphPad Prism 5® and expressed
as bound of [3H ]-CP55,940 (% vehicle). Ki values were calculated using the Cheng-Prusoﬀ equation: Ki
= IC50 / 1 + [L]/ Kd .
Chapter 4
Results and discussion
4.1 LC-MS/MS results
4.1.1 Kidney
MH (Figure 4.1) at the doses of 10mg/kg and 20mg/kg induced a signiﬁcant increase of AEA and 2AG
levels in kidney as compared to vehicle control (Figure 4.2a and 4.2b). Intriguingly, the minor endo-
cannabinoid noladin ether which was not detected in vehicle-treated animals and at the non-eﬀective dose
of 3mg/kg of MH, became detectable upon treatment with MH at the doses of 10mg/kg and 20mg/kg
(Figure 4.2c). The increase of AEA, 2AG and NE could be due to the eﬀect of MH on COX-2-mediated
endocannabinoids oxygenation. On the contrary, AA and prostaglandin E2 (PGE2) levels were not af-
fected by MH (Figure 4.3a e 4.3b). Prostaglandin D2 (PGD2) was below limit of detection. If MH had
exerted non-selective inhibition of COX-2 activity (meaning that also the catalytic subunit responsable
for the metabolism of AA was inhibited), a signiﬁcant decrease of PGE2 concentration and a consequent
increase of AA level should have been observed. Unfortunately, PG-GEs and PG-EAs were below the
limit of detection.
Altogether this data strongly indicated that MH acts as a COX-2 SSI in vivo.
We also measured the levels of the other N-acetylethanolamines (NAEs) and hormones. The levels
of PEA and OEA did not change while LEA showed an increase similarly to AEA (Figure 4.4). These
data are in line with the lack of FAAH inhibition for MH [49]. Beyond FAAH hydrolysis, LEA can be
metabolized by lypooxygenases and MH was shown to inhibit lypooxygenase-5 [50]. This could explain
the speciﬁc increase of LEA and not the other NAEs. Corticosterone and Progesterone levels were not
aﬀected by MH treatment (Figure 4.5).
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Figure 4.1: Kidney: MH
(a) (b) (c)
Figure 4.2: Kidney: AEA (a), 2AG (b), NE (c)
(a) (b)
Figure 4.3: Kidney: AA (a), PGE2 (b)
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(a) (b) (c)
Figure 4.4: Kidney: PEA (a), OEA (b), LEA (c)
(a) (b)
Figure 4.5: Kidney: Corticosterone (a), Progesterone (b)
CHAPTER 4. RESULTS AND DISCUSSION 34
4.1.2 Brain
The ability of MH to pass the blood brain barrier (BBB) in normal conditions was conﬁrmed in this
experiment (Figure 4.6a) in addition to the data showing that upon endotoxemia (LPS-induced), MH
can reach bioactive concentrations in the brain ([49]). The concentration of MH was in the same range
as a previous experiment made by Chicca et al. (Figure 4.6b). 2AG levels were not aﬀected by MH
treatment, while a decrease of AEA was observed (Figure 4.7). In the results shown by Chicca et al , a
similar behavior of AEA was measured but the levels of 2AG increased (Figure 4.8). This diﬀerence could
be explained with the LPS challenge which induce a systemic inﬂammation. In this condition, COX-2-
mediated oxygenation seems to be more relevant for 2AG metabolism, thus leading to a more pronounced
pharmacological eﬀect induced by MH. NE was not detectable in the brain, in accordance with literature.
A signiﬁcance decrease of AA levels could be seen with 20mg/kg of MH whereas PGE2 and PGD2 levels
were not aﬀected by the treatment (Figure 4.9).
In the brain PEA and OEA showed a similar decrease as AEA whereas LEA was only marginally
aﬀected (Figure 4.10). No signiﬁcant changes could be found in Corticosterone and Progesterone levels
(4.11).
(a) MH (2016) (b) MH adapted from Chicca et al Journal
of Neuroinﬂammation
Figure 4.6: Brain: MH
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(a) (b)
Figure 4.7: Brain: AEA(a), 2AG(b)
Figure 4.8: AEA and 2AG adapted from Chicca et al Journal of Neuroinﬂammation
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(a) (b) (c)
Figure 4.9: Brain: AA(a), PGE2(b), PGD2(c)
(a) (b) (c)
Figure 4.10: Brain: PEA(a), OEA(b), LEA(c)
(a) (b)
Figure 4.11: Brain: Corticosterone(a), Progesterone(b)
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4.1.3 Liver
Noticeable, like in the kidney, 2AG and AEA levels signiﬁcantly increased at 10mg/kg and 20mg/kg of
MH (Figure 4.12, 4.13a and 4.13b). A MH eﬀect could not be concluded with these values. Noladin-ether
showed a tendency to increase similar to AEA and 2AG. In particular, it was mostly non-detectable in
the control animals as well as mice trated with 3mg/kg of MH. In line with the data obtained in kidney,
NE levels became robustly detectable upon treatment with MH at 10 and 20 mg/kg (Figure 4.13c).
In the liver, a signiﬁcant increase of AA levels could be noticed at 10mg/kg of MH with a tendency
to increase at 20mg/kg of MH (Figure 4.14a). PGE2 level was below limit of quantiﬁcation while PGD2
levels only marginally detectable without changes induced by the treatments (Figure 4.14b).
Here, like in the kidney, when 2AG and AEA increased, a signiﬁcant increase of LEA respect to control
was observed, while PEA and OEA levels did not change (Figure 4.15). No signiﬁcant changes could be
found in Corticosterone and Progesterone (Figure 4.16).
Figure 4.12: Liver: MH
(a) (b) (c)
Figure 4.13: Liver: AEA(a), 2AG(b), NE(c)
CHAPTER 4. RESULTS AND DISCUSSION 38
(a) (b)
Figure 4.14: Liver: AA(a), PGD2(b)
(a) (b) (c)
Figure 4.15: Liver: PEA(a), OEA(b), LEA(c)
(a) (b)
Figure 4.16: Liver: Corticosterone(a), Progesterone(b)
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4.1.4 Lung
MH was quantiﬁable also in the lung and values are showed in Figure 4.17. The levels of AEA and 2AG
did not signiﬁcant change compared to control despite a tendency to increase upon treatment with MH
at 10 and 20mg/kg (Figure 4.18). NE was not detectable.
MH treatment did not aﬀect the levels of AA, while it strongly reduced PGE2 and PGD2 levels at all
three tested doses (Figure 4.19). Our data do not indicate whether this eﬀect was mediated via COX-2
inhibition because AA, 2AG and AEA levels were not aﬀected. Furthermore, the decrease of both PGs
was visible also at 3mg/kg of MH treatment while in the other organs, this dose did not show any signicant
eﬀects as compared to the control.
PEA and OEA levels did not signiﬁcantly change upon MH treatment, while LEA increased (Figure
4.20). The latter was not associated with an increase of AEA as observed in liver and kidney. Corticos-
terone and Progesterone levels were not aﬀected by MH treatment as compared to control also if a large
variability, especially in the Progesterone level, was observed (Figure 4.21).
Figure 4.17: Lung: MH
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(a) (b)
Figure 4.18: Lung: AEA(a), 2AG(b)
(a) (b) (c)
Figure 4.19: Lung: AA(a), PGE2(b), PGD2(c)
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(a) (b) (c)
Figure 4.20: Lung: PEA(a), OEA(b), LEA(c)
(a) (b)
Figure 4.21: Lung: Corticosterone(a), Progesterone(b)
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4.1.5 Spleen
The highest levels of MH were found in the spleen (around 5-10 times higher than the other tissues) (Figure
4.22). Due to the elevate concentration of immune cells which express CB2 receptors, it is possible that
MH reaches the spleen bound to the receptors rather than distribute in the tissue stroma. In fact, AEA
levels did not change while 2AG exhibited only a tendency to increase at the higher doses (Figure 4.23).
NE was not detectable.
The AA level in the spleen was not aﬀected, while concentration-dependent increase of both PGE2
and PGD2 levels was observed (Figure 4.24). This behavior seems to be in contrast with the COX-2
SSI eﬀect, where PG levels should not be aﬀected and with the activation of CB2 receptors which would
inhibit COX-2 expression. In addition, the PGs increase was not associated with a change in the AA
level. The mechanism of these eﬀects should be further investigates to understand the possible roles of
CB2 and/or COX-2.
PEA, OEA and LEA levels did not signiﬁcantly change and this eﬀect was coupled with no change in
endocannabinoid levels, like in the brain (Figure 4.25). Corticosterone levels seemed to be not aﬀected
by MH, despite some variability in 10mg/kg and 20mg/kg values (Figure 4.26). Progesterone was not
detectable.
Figure 4.22: Spleen: MH
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(a) (b) (c)
Figure 4.24: Spleen: AA(a), PGE2(b), PGD2(c)
(a) (b)
Figure 4.23: Spleen: AEA(a), 2AG(b)
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(a) (b) (c)
Figure 4.25: Spleen: PEA(a), OEA(b), LEA(c)
Figure 4.26: Spleen: Corticosterone
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4.2 CB2 receptor binding assay
In order to conﬁrm the binding activity of MH to a CB2 receptor, some binding assays were repeated.
The Ki value was calculated using the Cheng-Prusoﬀ equation (Ki = IC50/ 1 + [L]/Kd) and resulted
in 660nM (95% CI, 549-792) for MH and 2.3nM (95% CI, 1.8-2.9) for (R)-WIN55,212-2. The Ki value
obtained for MH is comparable with the aﬃnity reported in the literature and previously measured in the
group of Prof. J.Gertsch [49] (Figure 4.27).
Figure 4.27: CB2 receptor binding for MH and (R)-WIN55,212-2
4.3 Overview
MH acts as a CB2 receptor agonist and as a COX-2 SSI. In order to understand whether some of the eﬀects
showed in the experiment were due to one or both targets, additional experiments will be performed. For
example, one experiment should be performed in mice treated with MH, a CB2 agonist, a COX-2 inhibitor
and a combination of both. The comparison of the diﬀerent treatments, could provide compelling evidence
to better understand the mechanisms of action of MH.
Alternative experiments could be carried out injecting MH in CB2 and COX-2 knock-out animals.
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